Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edralbrutinib - Eternity Bioscience/TG Therapeutics

Drug Profile

Edralbrutinib - Eternity Bioscience/TG Therapeutics

Alternative Names: EBI-1459; SHR-1459; TG-1701

Latest Information Update: 13 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eternity Bioscience
  • Developer Eternity Bioscience; Jiangsu Hengrui Medicine Co.; Reistone Biopharma; TG Therapeutics
  • Class Amines; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenyl ethers; Pyridazines; Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Membranous glomerulonephritis; Neuromyelitis optica; Non-Hodgkin's lymphoma
  • Phase I B-cell lymphoma; Chronic lymphocytic leukaemia
  • Preclinical Mantle-cell lymphoma; Multiple sclerosis

Most Recent Events

  • 13 Feb 2023 Edralbrutinib is still in phase I trials for B cell lymphoma in China (PO)
  • 13 Feb 2023 Jiangsu HengRui Medicine completes a phase I pharmacokinetic trial (In volunteers) for B-cell lymphoma in China (PO) (NCT05560360)
  • 04 Nov 2022 Jiangsu HengRui Medicine initiates a phase I pharmacokinetic trial (In volunteers) for B-cell lymphoma in China (PO) (NCT05560360)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top